Cullinan Therapeutics (CGEM) Long-Term Debt Issuances (2022)
Cullinan Therapeutics (CGEM) posted quarterly Long-Term Debt Issuances of $1.4 million for Q2 2022, up 75.0% quarter-over-quarter from $800000.0 in Q1 2022.
Powered by 
Analysis
Cullinan Therapeutics (CGEM) Long-Term Debt Issuances (2022) Analysis & Trends
Cullinan Therapeutics' Long-Term Debt Issuances history runs 1 years deep, the most recent figure standing at $1.4 million for Q2 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Cullinan Therapeutics | 1.37 Bn | 1.37 Bn | - | - |